Target Name: CDH19
NCBI ID: G28513
Review Report on CDH19 Target / Biomarker Content of Review Report on CDH19 Target / Biomarker
CDH19
Other Name(s): CAD19_HUMAN | cadherin 19, type 2 | cadherin 19 | Cadherin 19, transcript variant 2 | CDH7L2 | Cadherin 19, transcript variant 1 | Cadherin-19 (isoform 2) | CDH19 variant 1 | CDH19 variant 2 | Cadherin-19 | CDH7 | Cadherin-19 (isoform 1)

CDH19: A Potential Drug Target and Biomarker for the Treatment of CAD19

Abstract:

CAD19 (Cadherin-19) is a gene that encodes a protein involved in cell-cell adhesion. The most promising candidate for a drug target in this gene is CDH19. This article discusses the biology of CDH19, its potential as a drug target, and the current research on its use as a biomarker for the treatment of CAD19.

Introduction:

Cadherins are a family of transmembrane proteins that play a central role in cell-cell adhesion. The loss of cadherins has been implicated in many diseases, including cancer, neurodegenerative diseases, and developmental disorders. The protein encoded by the CDH19 gene has been shown to be a key regulator of cell-cell adhesion and has been linked to the development and progression of many diseases.

CDH19: A Potential Drug Target:

CDH19 has been identified as a potential drug target due to its involvement in cell-cell adhesion and its role in several diseases. Its function in cell-cell adhesion allows it to regulate the movement and behavior of cells, and its abnormal expression has been linked to the development of cancer.

CDH19 has been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that CDH19 is overexpressed in many types of cancer, including breast, ovarian, and colorectal cancer. This overexpression is associated with the development of cancer stem cells, which are responsible for the maintenance and growth of cancer.

In addition to its role in cancer, CDH19 has also been linked to the development of neurodegenerative diseases. Studies have shown that CDH19 is overexpressed in the brains of individuals with Alzheimer's disease and other forms of neurodegenerative disease. This overexpression is thought to contribute to the development and progression of these diseases.

CDH19 as a Biomarker:

CDH19 has also been shown to be a potential biomarker for the treatment of CAD19. CAD19 is a disease that is characterized by the loss of cell-cell adhesion and is often associated with the development of cancer and neurodegenerative diseases.

Studies have shown that CDH19 can be used as a biomarker for the treatment of CAD19 by measuring its expression in patient samples. For example, studies have shown that the expression of CDH19 is decreased in the brains of individuals with CAD19, and that this decrease is associated with the treatment response to anti-CAD19 therapies.

In addition, studies have also shown that CDH19 can be used as a biomarker for the detection of disease-specific biomarkers in patients with CAD19. For example, studies have shown that the expression of CDH19 is associated with the development of certain diseases, such as cancer and neurodegenerative diseases, and that the expression of CDH19 can be used as a biomarker for the detection of these diseases.

Conclusion:

CDH19 is a gene that has been shown to play a role in cell-cell adhesion and is associated with the development and progression of many diseases. Its potential as a drug target and biomarker make it an attractive target for further research. Further studies are needed to fully understand the role of CDH19 in disease and to develop effective treatments.

Protein Name: Cadherin 19

Functions: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types

The "CDH19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDH19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1 | CDON | CDPF1 | CDR1 | CDR2 | CDR2L | CDRT15 | CDRT15L2 | CDRT4 | CDRT7 | CDS1 | CDS2 | CDSN | CDT1 | CDV3 | CDX1 | CDX2 | CDX4 | CDY1 | CDY1B | CDY2A | CDYL | CDYL2 | CEACAM1 | CEACAM16 | CEACAM16-AS1